Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU

Pfizer (PFE) announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients.With this nod, the once-weekly Hympavzi gets approved for routine prophylaxis (RP) to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B, without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). Following this approval, Hympavzi became the first hemophilia medicine approved in the Unite ...